2 weeks Ago By Defense World Staff
Dimensional Fund Advisors LP increased its holdings in shares of Bio-Techne Co. ( NASDAQ:TECH – Free Report ) by 9.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
The institutional investor owned 894,352 shares of the biotechnology company’s stock after acquiring an additional 76,641 shares during the period. Dimensional Fund Advisors LP owned approximately 0.57% of Bio-Techne worth $64,082,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in TECH. Brown Brothers Harriman & Co. lifted its position in Bio-Techne by 922.
5% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 409 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 369 shares in the last quarter.
Industrial Alliance Investment Management Inc. purchased a new stake in shares of Bio-Techne in the second quarter worth $31,000. DT Investment Partners LLC purchased a new stake in shares of Bio-Techne during the second quarter worth about $36,000.
Mather Group LLC. bought a new stake in Bio-Techne in the 1st quarter valued at $38,000. Finally, Versant Capital Management Inc boosted its position in shares of Bio-Techne by 1,427.
8% during the 2nd quarter. Versant Capital Management Inc now owns 550 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 514 shares during the last quarter. 98.
95% of the stock is owned by institutional investors. Wall Street Analyst Weigh In A number of analysts recently issued reports on TECH shares. Robert W.
Baird raised their price target on Bio-Techne from $81.00 to $82.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th.
Royal Bank of Canada reduced their price objective on shares of Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating for the company in a research note on Thursday, August 8th.
Finally, Benchmark reiterated a “buy” rating and issued a $95.00 target price on shares of Bio-Techne in a research note on Tuesday, August 13th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company.
Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $80.60.
Bio-Techne Price Performance TECH stock opened at $78.72 on Friday. The business has a 50 day moving average price of $75.
24 and a 200 day moving average price of $74.05. Bio-Techne Co.
has a fifty-two week low of $51.79 and a fifty-two week high of $85.57.
The company has a quick ratio of 2.75, a current ratio of 3.87 and a debt-to-equity ratio of 0.
15. The stock has a market cap of $12.49 billion, a price-to-earnings ratio of 62.
48, a PEG ratio of 5.59 and a beta of 1.27.
Bio-Techne ( NASDAQ:TECH – Get Free Report ) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.
49. Bio-Techne had a net margin of 14.50% and a return on equity of 12.
88%. The company had revenue of $306.10 million for the quarter, compared to the consensus estimate of $306.
49 million. During the same period last year, the firm posted $0.56 EPS.
Bio-Techne’s revenue for the quarter was up 1.6% on a year-over-year basis. Equities research analysts anticipate that Bio-Techne Co.
will post 1.7 earnings per share for the current fiscal year. Bio-Techne Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Friday, August 30th.
Investors of record on Monday, August 19th were paid a $0.08 dividend. The ex-dividend date was Monday, August 19th.
This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.41%.
Bio-Techne’s dividend payout ratio (DPR) is presently 25.40%. About Bio-Techne ( Free Report ) Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
Recommended Stories Five stocks we like better than Bio-Techne Do Real Estate Investment Trusts Deserve a Place in Your Portfolio? Can Costco Stock Hit New Highs as Interest Rates Drop? What Does Downgrade Mean in Investing? These 3 Stocks Show How to Navigate Declining Consumer Confidence Stock Trading Terms – Stock Terms Every Investor Needs to Know MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy? Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Co. ( NASDAQ:TECH – Free Report ).
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter ..
